Novartis has gained access to Singulex’ biomarker detection technology through an Erenna™ Technology Access Program (ETAP). The Erenna system has been placed at Novartis’ Basel, Switzerland facility. The companies will work together to develop assays to advance Novartis’ drug development programs.
Erenna and accompanying assays are designed to measure low levels and small changes of protein biomarkers across a variety of biological samples from multiple species.
